Cooper (COO) Q2 2026 Earnings Transcript

The Cooper Companies reported record quarterly revenue of $1.08 billion, up 8% year over year, and non-GAAP EPS of $1.21, up 26%, while operating margin expanded to 27.5%. Management raised full-year free cash flow guidance to about $650 million and signaled more aggressive buybacks, but lowered CooperVision revenue expectations due to persistent Asia Pacific softness and FX/tariff pressure. A $271.6 million litigation charge tied to the CooperSurgical embryo media recall was disclosed, though it was excluded from non-GAAP results and most of the process is now settled.

Analysis

The setup is better for the equity than the headline numbers imply because the next leg is less about operating acceleration and more about capital structure optionality. If CooperSurgical attracts a credible bid, the equity becomes a sum-of-parts event: a monetized non-core asset could fund a much larger repurchase program against a still-depressed remaining business, mechanically lifting per-share value even if consolidated growth slows. That creates a cleaner catalyst stack than a normal beat/raise, because the market can re-rate on disclosure of process, not just closing certainty.

The market is likely underestimating how much of the near-term margin pressure is self-inflicted and reversible. Inventory reduction tied to AI tools is suppressing gross margin now, but that is a cash-flow positive, not a demand problem; once the destocking cycle normalizes, the incremental margin on higher production should inflect without requiring much top-line improvement. The second-order winner is the balance sheet: lower inventory plus asset-sale proceeds would compound buybacks, so per-share EPS growth could outrun reported revenue for several quarters.

The main bear case is that Asia-Pacific weakness is not just cyclical but behavioral, with e-commerce and wear-pattern shifts taking share from the company’s fitter-led model. If that proves sticky through 2027, then the multiple on the remaining contact lens business deserves a discount because the mix shift is eroding pricing power exactly where management wants to migrate users into premium products. Consensus seems too willing to treat APAC as a temporary macro issue; the risk is that it becomes a structural channel and product-mix problem that caps organic growth even as the company executes elsewhere.

Key Decisions for Investors

• Long COO common over a 3-6 month horizon into strategic-review updates; asymmetry improves if the market starts pricing a CSI transaction plus accelerated buybacks. Risk: APAC deterioration persists and the stock remains range-bound if no process milestone lands.
• Pair trade: long COO / short a premium medical-device basket ETF or high-multiple medtech name over 1-2 quarters. Thesis: COO has a specific catalyst stack (sale process, buybacks, cash flow) that can de-couple from broader medtech de-rating; risk is a broad risk-on tape that lifts the whole sector.
• Buy COO Jan-2027 calls financed by selling nearer-dated upside or cash-secured puts. This captures optionality on a CSI sale and buyback acceleration while limiting downside to a time-bound execution window; risk/reward is attractive if a transaction headline lands before year-end.
• If pursuing a relative-value trade, pair long COO against short a contact-lens peer with higher APAC exposure. COO’s global premium mix and capital return catalyst should outperform if the market continues to punish consumer softness in Asia; risk is a fast APAC stabilization that lifts the short leg.
• Take profits on any pre-event squeeze after a strategic-process headline unless there is explicit transaction economics. The first re-rating is likely on process visibility; the second leg requires either a signed deal or a materially larger buyback authorization.